# GLP-1 Drugs For Weight Loss: Wegovy, Saxenda, Ozempic and semaglutide explained
Author: Dr. Amelia Shah, MBBS, MRCGP, PgCert Obesity Medicine
Author URL: https://www.piko.com/blog/author/dr-amelia-shah-mbbs-mrcgp-pgcert-obesity-medicine
Published: 2025-11-24
Category: GLP-1
Category URL: https://www.piko.com/blog/category/glp-1
Meta Title: GLP-1 Drugs For Weight Loss
Meta Description: Understand how GLP-1 drugs like Wegovy, Saxenda and semaglutide support weight loss, who they’re for, and the key benefits and risks in the UK.
Tags: GLP-1 Drugs For Weight Loss, glp1 for weight loss, semaglutide weight loss, semaglutide injection, semaglutide glp 1
Tag URLs: GLP-1 Drugs For Weight Loss (https://www.piko.com/blog/tag/glp-1-drugs-for-weight-loss), glp1 for weight loss (https://www.piko.com/blog/tag/glp1-for-weight-loss), semaglutide weight loss (https://www.piko.com/blog/tag/semaglutide-weight-loss), semaglutide injection (https://www.piko.com/blog/tag/semaglutide-injection), semaglutide glp 1 (https://www.piko.com/blog/tag/semaglutide-glp-1)
URL: https://www.piko.com/blog/glp-1-drugs-for-weight-loss

![](https://prod.superblogcdn.com/site_cuid_cmid8any6015qqk0dcsyi3a1x/images/generated-image-november-24-2025-318pm-1763997561836-compressed.jpeg)

If you’ve been hearing about **“Ozempic”**, **“the diabetes weight loss drug”** or **“GLP-1 for weight loss”** on the news or social media, it can be hard to tell:

- Which medicines are actually licensed for **weight loss**

- How **semaglutide weight loss injections** differ from standard diabetes treatments

- Whether it’s safe or legal to get **Ozempic without prescription** online


This guide breaks down:

- What **GLP-1 drugs for weight loss** are and how they work

- The differences between **Wegovy, Saxenda and Ozempic**

- UK licensing and who they’re intended for

- Typical results, side-effects and safety issues

- Why **prescription and proper monitoring** are essential


Throughout, remember: these are **prescription-only medicines in the UK**, and this article doesn’t replace medical advice from your own doctor.

* * *

## What are GLP-1 drugs – and how do they help with weight loss?

**GLP-1 receptor agonists** (often shortened to “GLP-1s”) are medicines that mimic a natural hormone called **GLP-1 (glucagon-like peptide-1)**.

They were originally developed as **diabetes meds**, but some of them also produce meaningful weight loss, which led to specific **weight management licences**.

### Mechanism in simple terms

GLP-1 drugs like **semaglutide** and **liraglutide** help with:

- **Appetite control** – they act on areas of the brain that regulate hunger and fullness, so you feel full sooner and have fewer cravings.

- **Slower stomach emptying** – food stays in your stomach longer, which prolongs satiety and smooths blood sugar rises after meals.

- **Better blood sugar control** – they increase insulin release _when blood sugar is high_ and reduce glucagon, improving glucose levels in people with type 2 diabetes.


Because of this combination, **GLP-1 for weight loss** typically makes it easier to:

- Eat less without feeling as deprived

- Stick to a reduced-calorie diet

- Lose weight and improve metabolic health over time


* * *

## Which GLP-1 drugs are used for weight loss in the UK?

The key names you’ll see are:

- **Wegovy® (semaglutide)** – _licensed for weight management_

- **Saxenda® (liraglutide)** – _licensed for weight management_

- **Ozempic® (semaglutide)** – _licensed for type 2 diabetes, not for weight loss_

- **Semaglutide** – the active ingredient in both Wegovy and Ozempic (and oral **Rybelsus®** for diabetes)


So when people talk about:

- **“semaglutide weight loss” / “semaglutide for weight loss”** → they usually mean **Wegovy**, which is **semaglutide GLP-1** specifically licensed for weight management.

- **“diabetes meds to lose weight” / “best diabetes drug for weight loss”** → they’re often referring to GLP-1s developed for diabetes that also cause weight loss as a side-effect (like Ozempic), even though not all of them are licensed _as weight loss drugs_.


* * *

## Wegovy vs Saxenda vs Ozempic: key differences

Below is a simplified comparison of the most commonly discussed GLP-1 medicines in the UK.

> Always check the official patient leaflet and talk to a doctor or pharmacist for the most up-to-date details.

MedicineMain UK indicationActive ingredient & classDosing frequencyRouteTypical side-effects (class)**Wegovy®**Weight management in adults with obesity/overweight plus risk factors, within specialist weight management services (NICE TA875).**Semaglutide**– GLP-1 receptor agonist**Once weekly** injection, dose slowly increasedSubcutaneous injection (pre-filled pen)Nausea, vomiting, diarrhoea/constipation, abdominal pain, reduced appetite, headache; rare but serious: pancreatitis, gallbladder issues.**Saxenda®**Weight management in adults with obesity or overweight with at least one weight-related comorbidity, as adjunct to diet and activity.**Liraglutide**– GLP-1 receptor agonist**Once daily** injection, dose built up over weeksSubcutaneous injection (pre-filled pen)Similar GLP-1 side-effects: nausea, diarrhoea/constipation, abdominal discomfort, possible gallbladder issues and pancreatitis.**Ozempic®**Treatment of adults with type 2 diabetes inadequately controlled on diet/exercise ± other meds; **not licensed for weight loss**.**Semaglutide**– GLP-1 receptor agonist**Once weekly** injection, dose titrated upSubcutaneous injection (pre-filled pen)Same GLP-1 class side-effects; careful monitoring needed in diabetes (risk of low blood sugar when combined with other meds).**Rybelsus®**(for context)Oral semaglutide for type 2 diabetes (not licensed for weight loss)**Semaglutide**– GLP-1 receptor agonist**Once daily oral tablet**OralSimilar class side-effects; extra guidance around taking on empty stomach.

In other words:

- **Wegovy and Saxenda** = GLP-1 **weight loss drugs** in the UK.

- **Ozempic and Rybelsus** = GLP-1 **diabetes medicines** that can cause weight loss but are **not licensed as weight loss treatments**.


* * *

## What does the evidence say about GLP-1 for weight loss?

### Semaglutide (Wegovy) for weight loss

Large clinical trials (the STEP programme) looked at **semaglutide 2.4 mg once-weekly** in people with obesity or overweight plus comorbidities, alongside lifestyle changes:

- Average weight loss of **around 15% of starting body weight** over 68 weeks with Wegovy + lifestyle, compared with much less on lifestyle alone.

- A significant proportion of patients achieved **≥10% or ≥15%** weight loss.


This is why semaglutide weight loss injections are often described as a major step-change in medical obesity treatment.

### Liraglutide (Saxenda) for weight loss

Trials of **liraglutide 3.0 mg daily** showed:

- Average weight loss of around **5–8% of body weight** over about 1 year, again combined with diet and exercise support.

- More patients reaching clinically meaningful weight loss thresholds compared with placebo.


### Ozempic (semaglutide) in diabetes

Ozempic is studied and licensed for **type 2 diabetes**, not obesity, but:

- Diabetes trials show **improved glycaemic control and weight loss** compared with some other diabetes meds.

- Because of this, people sometimes see it as the **“best diabetes drug for weight loss”**, even though its primary goal is glucose control.


Across the GLP-1 class, research shows improvements not just in weight, but in **blood sugar, blood pressure, lipids and cardiovascular risk markers** for many patients.

> Important: Clinical trial averages are **not guarantees**. Some people lose less, some don’t respond well, and a few cannot tolerate the medicine at all.

* * *

## Who are GLP-1 weight loss drugs for in the UK?

UK rules are quite specific – especially on the **NHS**.

### NHS use (Wegovy & Saxenda)

NICE recommends **semaglutide (Wegovy)** and **liraglutide (Saxenda)** for weight management only under certain conditions, typically:

- Adults with **BMI ≥ 35 kg/m²** plus at least **one weight-related condition** (for example, type 2 diabetes, high blood pressure, sleep apnoea), **or**

- Adults with **BMI 30–34.9 kg/m²** and similar risk factors, where they also qualify for a **specialist weight management (Tier 3) service**

- Lower BMI thresholds may apply for some ethnic groups because of higher risk at lower BMI.


NHS guidance usually limits:

- **Where** they can be prescribed (specialist clinics, not routine GP prescribing)

- **How long** they’re used (e.g. Wegovy often for up to 2 years, stopping if insufficient weight loss)


### Private clinics

Private weight management services may offer Wegovy or Saxenda using the **licensed weight loss indications**, such as:

- BMI **≥ 30 kg/m²**, or

- BMI **≥ 27 kg/m² with at least one weight-related comorbidity**


But even privately, a clinician still has to:

- Take a **full medical history**

- Check current medications and interactions

- Assess **risks vs benefits**

- Provide ongoing **monitoring and support**


GLP-1 drugs are **not intended** for people who just want to “drop a few pounds” for cosmetic reasons. Regulatory guidance stresses they should be reserved for those who are overweight or obese with health risks.

* * *

## Side-effects, risks and safety

### Common side-effects

Across GLP-1 medications, the most common side-effects are gastrointestinal:

- Nausea / feeling sick

- Vomiting

- Diarrhoea or constipation

- Abdominal pain, bloating or indigestion

- Loss of appetite (sometimes too strong)

- Headache, dizziness

- Injection-site reactions


These are often dose-related and may improve over time or with slower dose escalation.

### More serious but less common risks

Important but less common issues include:

- **Gallbladder problems and gallstones**

- **Pancreatitis** (inflammation of the pancreas) – can be severe

- Possible worsening of **diabetic retinopathy** in some people with rapid improvements in blood sugar

- Concerns around **delayed stomach emptying** and anaesthesia, leading to new pre-surgery advice for some patients on GLP-1 RAs

- Potential interactions with **oral contraception** due to vomiting/diarrhoea reducing pill effectiveness.


Because of these risks, regulators in the UK repeatedly emphasise:

- Only use GLP-1 medicines **under medical supervision**

- Only for **licensed indications**

- Report side-effects through schemes like the **MHRA Yellow Card**.


* * *

## “Ozempic without prescription”: why it’s unsafe and illegal

Searches like **“Ozempic without prescription”** or “buy Ozempic online UK” have exploded – but there are big problems here.

In the UK:

- **Ozempic, Wegovy, Saxenda and other GLP-1s are Prescription-Only Medicines (POMs).**

- That means they **must** be prescribed by an authorised prescriber and dispensed by a regulated pharmacy.


Getting them **without a valid prescription**, for example:

- From social media “sellers”

- From beauty salons or gyms

- From unregulated websites or overseas suppliers


is both **illegal** and **high-risk**, because:

1. **You may not get the right drug or dose**

   - Counterfeit and mislabelled injectables are a known problem globally.
2. **No proper medical checks**

   - No assessment of your BMI, medical history, other medicines, pregnancy plans or mental health.
3. **No monitoring**

   - No one to adjust dose, manage side-effects or decide when to stop.
4. **No accountability**

   - If something goes wrong, you have limited protection or recourse.

The UK government and MHRA have specifically warned about **misuse, off-label use and supply of GLP-1s via unofficial routes**, and emphasise that they should only be used for their licensed purposes.

If a site offers “cheap **weight loss drug Ozempic** with no questions asked”, treat that as a huge red flag.

* * *

## Choosing between Wegovy, Saxenda and other options

You can’t – and shouldn’t – decide this alone. But it helps to understand the general differences:

- **Wegovy (semaglutide weight loss)**

  - Once-weekly semaglutide injection

  - Typically produces the **largest average weight loss** among the GLP-1 weight loss drugs, based on current evidence.
- **Saxenda (liraglutide weight loss)**

  - Once-daily injection

  - Long track record; weight loss averages are lower than with Wegovy, but still clinically meaningful.
- **Ozempic (semaglutide for diabetes)**

  - Once-weekly semaglutide injection

  - Licensed for **type 2 diabetes**; any use as a **“diabetes weight loss drug”** must still be within its diabetes indication and under proper supervision.

Your doctor or weight-management clinician will consider:

- Your **BMI and health conditions**

- Whether you have **type 2 diabetes, pre-diabetes or other risks**

- Past response to lifestyle changes and other treatments

- Safety considerations (kidney, liver, pancreatic, gallbladder, endocrine history, pregnancy plans)

- Your ability to attend follow-up and make parallel **lifestyle changes**


Often, the real question is not “What is the **best diabetes drug for weight loss**?” but “What is the **safest, most appropriate overall plan** for _my_ health over the long term?”

* * *

## Where to learn more next (internal links)

If your site has individual posts for each medicine, you can guide readers deeper:

- **Wegovy deep-dive:** indications, dosing, timelines and expected results

  → e.g. `/blog/wegovy-weight-loss-guide`

- **Saxenda deep-dive:** daily dosing, who it suits best, and pros/cons vs Wegovy

  → e.g. `/blog/saxenda-weight-loss-liraglutide`

- **Ozempic & semaglutide deep-dive:** diabetes focus, off-label questions and safety

  → e.g. `/blog/ozempic-semaglutide-diabetes-and-weight-loss`


Linking these from this **GLP-1 overview hub** helps users (and search engines) understand how your content fits together and find the specific answers they’re looking for.

* * *

### Key takeaways

- **GLP-1 drugs for weight loss** (mainly **Wegovy** and **Saxenda** in the UK) work by **reducing appetite, slowing digestion and improving blood sugar control**.

- **Semaglutide weight loss injections** (Wegovy) can lead to **~15% average weight loss** in trials, while Saxenda averages ~5–8% – but results vary and are never guaranteed.

- **Ozempic** is a **semaglutide GLP-1** licensed for **type 2 diabetes**, not for obesity, even though it also causes weight loss.

- All GLP-1s carry **gastrointestinal side-effects** and rare but serious risks like **pancreatitis and gallbladder disease**, which is why **doctor supervision is essential**.

- Getting **Ozempic without prescription** or buying GLP-1s from unregulated sources is **unsafe and illegal** in the UK. Stick to regulated, prescription-only routes.


If you’re considering GLP-1 treatment, the safest next step is to speak with a regulated UK provider or your GP, discuss your health history in detail, and explore whether a GLP-1 medicine – combined with structured lifestyle support – is the right option for you.


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---